Discover 604 paid clinical trials in Lincoln, Nebraska. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Lincoln offers a wide variety of trials focused on numerous chronic conditions like diabetes, mental health disorders, and cardiovascular diseases. Participants, including healthy volunteers seeking paid research opportunities or those with a particular health condition, can explore new treatment options while contributing to the development of groundbreaking therapies.
Filter
2
Filter results
Results: 604
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
for
Head and Neck Squamous Cell Carcinoma (HNSCC)
Location: Omaha NE, Evanston IL, Lubbock TX, Louisville KY,
Sponsor: Regeneron Pharmaceuticals
Sex: All
Age: 18+
Code: NCT06769698
Phase2, Recruiting
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
for
Gastrointestinal Neoplasms
Location: Omaha NE, Overland Park KS, Iowa City IA, Rochester MN,
Sponsor: GlaxoSmithKline
Sex: All
Age: 18+
Code: NCT07218926
Phase3, Recruiting
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
for
Breast Neoplasms
Location: Omaha NE, Grand Island NE, Kansas City MO,
Sponsor: BioNTech SE
Sex: All
Age: 18+
Code: NCT07173751
Phase3, Recruiting
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
for
Prostate Cancer
Location: Omaha NE, Kansas City KS, Iowa City IA, St Louis MO,
Sponsor: Novartis Pharmaceuticals
Sex: Male
Age: 18 - 70+
Code: NCT06855277
Phase3, Recruiting
Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
for
Breast Cancer, Non-small Cell Lung Cancer (NSCLC),
Location: Omaha NE, Montreal
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 18+
Code: NCT07660055
Phase1, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
for
Metastatic Non-small Cell Lung Cancer With MTAP Deletion
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
for
CLL, Chronic Lymphocytic Leukemia
Location: Omaha NE, Springfield MO, Minneapolis MN,
Sponsor: BeOne Medicines
Sex: All
Age: 18+
Code: NCT06846671
Phase3, Recruiting
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
for
Prostate Cancer
Location: Omaha NE, Kansas City KS, St Louis MO, Denver CO,
Sponsor: Novartis Pharmaceuticals
Sex: Male
Age: 18 - 70+
Code: NCT06780670
Phase2, Phase3, Recruiting
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Location: Omaha NE, Des Moines IA, Iowa City IA, St Louis MO,
Sponsor: Shanghai Henlius Biotech
Sex: All
Age: 18+
Code: NCT06532006
Phase3, Recruiting
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
for
Early Breast Cancer
Location: Omaha NE, Kansas City MO, Sioux Falls SD,
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 18 - 70+
Code: NCT05827081
Phase3, Recruiting
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
for
Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm,
Location: Omaha NE, Kansas City KS, Rochester MN, Springfield IL,
Sponsor: BriaCell Therapeutics Corporation
Sex: All
Age: 18+
Code: NCT06072612
Phase3, Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
for
Metastatic Castration-resistant Prostate Cancer (mCRPC),